Literature DB >> 3168394

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

E Steiner1, L Bertilsson, J Säwe, I Bertling, F Sjöqvist.   

Abstract

The metabolic ratios (MRs) between debrisoquin and 4-hydroxydebrisoquin in urine after a single oral dose of 10 mg debrisoquin were bimodally distributed in 757 healthy, white Swedish volunteers. Forty-one subjects (5.4%) had an MR greater than 12.6 and were classified as slow debrisoquin hydroxylators. The MR was reproducible in urine stored at +8 degrees C for 1 week and at -20 degrees C over a period of 5 years. Collection intervals of 6 or 12 hours gave the same MR. Intraindividual repeatability of the debrisoquin phenotyping test was established in 37 subjects examined twice at least 2 weeks apart. The calculated frequency of the single allele that is believed to control deficient debrisoquin hydroxylation is similar among white Swedish people, as among other white groups examined so far; however, it is significantly different from the frequency in certain Oriental groups. Detailed comparisons of the prevalence of slow debrisoquin hydroxylation in different ethnic groups are not possible due to shortcomings in current epidemiologic techniques used (small materials, the location of the antimode distinguishing rapid and slow hydroxylators unknown, and family studies missing).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168394     DOI: 10.1038/clpt.1988.176

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  41 in total

1.  Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

2.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

3.  Pharmacokinetics of oral noscapine.

Authors:  M O Karlsson; B Dahlström; S A Eckernäs; M Johansson; A T Alm
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.

Authors:  O Gudjonsson; E Sanz; G Alván; S M Aquilonius; J Reviriego
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

5.  Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province).

Authors:  Mohammad Reza Shiran; Fatemeh Sarzare; Fatemeh Merat; Ebrahim Salehifar; Ali Akbar Moghadamnia; Seyed Mohammad Bagher Hashemi Soteh
Journal:  Caspian J Intern Med       Date:  2011

6.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.

Authors:  I Johansson; Q Y Yue; M L Dahl; M Heim; J Säwe; L Bertilsson; U A Meyer; F Sjöqvist; M Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects.

Authors:  Y Aden-Abdi; T Villén; O Ericsson; L L Gustafsson; M L Dahl-Puustinen
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

Review 8.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

9.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

10.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.